- Conditions
- Stage III Colon Cancer
- Interventions
- Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
- Device · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1045
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 730 more
Location Directory
Clinical trials in Baltimore, Maryland
This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13749
Shown on this page
12
Current sort
Recently updated
Location scope
Baltimore, MD
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 505–516 of 13,749 matching trials in Baltimore, MD.
Live ClinicalTrials.gov results.
Institutions in Baltimore
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Autism Spectrum Disorder, Anxiety Disorders
- Interventions
- DINOSAUR, Psychoeducation
- Behavioral · Other
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
- Interventions
- Digoxin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 15 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 188
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more
- Conditions
- Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
- Interventions
- Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- St. Petersburg, Florida • Baltimore, Maryland • New York, New York + 2 more
- Conditions
- Vestibular Schwannoma
- Interventions
- AAVAnc80-antiVEGF via Akouos Delivery Device
- Combination Product
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Interventions
- 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
- Procedure
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 45 Years to 70 Years
- Enrollment
- 9,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2065
- U.S. locations
- 484
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 328 more
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
- Interventions
- Non-interventional Study
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 488
- States / cities
- Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 378 more
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hodgkin Lymphoma
- Interventions
- pembrolizumab, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, etoposide, Radiotherapy (RT)
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Solid Tumors
- Interventions
- Navlimetostat, Daraxonrasib, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel, Cisplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more